606101-58-0

Basic information

• Product Name: MK-0773
• Synonyms: MK-0773;PF 05314882;PF05314882;PF-05314882;N-(3H-Imidazo[4,5-b]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
• CAS NO: 606101-58-0
• Molecular Formula: C₂₇H₃₄FN₅O₂
• Molecular Weight: 479.5895632
• Mol File: 606101-58-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 754.2±60.0 °C(Predicted)
• Appearance: /
• Density: 1.31±0.1 g/cm3(Predicted)
• PKA: 10.29±0.40(Predicted)
• CAS DataBase Reference: MK-0773(CAS DataBase Reference)
• NIST Chemistry Reference: MK-0773(606101-58-0)
• EPA Substance Registry System: MK-0773(606101-58-0)

Safety Data

• Hazardous Substances Data: 606101-58-0(Hazardous Substances Data)

Usage

General Description

MK-0773 is a type of selective androgen receptor modulator (SARM) that is commonly used in medical and pharmaceutical research. It has been studied for its potential use in the treatment of conditions such as osteoporosis and muscle wasting diseases. MK-0773 binds to androgen receptors in the body, which can influence the growth and development of muscles and bones. However, unlike other androgenic compounds, it is thought to offer these benefits without the adverse side effects typically associated with steroids. As of now, MK-0773 is not approved by the FDA for medical use.

Upstream product

• 606101-79-5 (5α,17β)-2-Fluoro-3-oxo-4-methyl-4-azaandrost-1-ene-17-carboxylic acid 

Relevant articles and documents

Salt of an androgen receptor modulator

The biphthalate salts of compound I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can

Process for making fluorinated 4-azasteroid derivatives

The present invention relates to synthetic processes useful in the preparation of fluorinated 4-azasteroid derivatives that modulate androgen receptors and have application in the treatment of conditions caused by androgen deficiency or androgen receptor hyperactivity, such as osteoporosis, periodontal disease, bone fracture, frailty, erectile dysfunction, loss of libido, androgen-dependent cancers and sarcopenia. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.